Zhang Fang, female, doctoral student, associate professor, master tutor, director of pharmacoeconomics teaching and research section.She received a Bachelor of Science degree from Shenyang Agricultural University in 1995, a Master of Science degree from Shenyang Pharmaceutical University in 2001, and a Doctor of Science degree from Shenyang Pharmaceutical University in 2005. Lectures on "Health Economics" for postgraduate students, "Health Economics" and "Pharmaceutical Economics" for undergraduates. Main research direction: health economic policy evaluation and pharmacoeconomic methodology research. Presided over more than 30 projects above the provincial and ministerial level. Published more than 200 papers, 5 of which were included in SCI. Published 2 books. Won 1 second prize of Liaoning Province Science and Technology Progress Award and 1 first prize of Shenyang Science and Technology Progress Award. The first prize of the National TRIZ Cup Innovation Competition, the special prize of the Liaoning Province TRIZ Cup Innovation and Entrepreneurship Competition, the Liaoning Provincial Education Evaluation Association Outstanding Paper Award, and the Shenyang Social Science Academic Achievement Award. In 2010, as a visiting scholar sent by the China Scholarship Council to study at the University of Newcastle, Australia.
Title of talents, social part-time jobs, etc
1.Co-chair of ISPOR (International Association for the Study of Pharmaceutical Economics and Results) Asian Journal of Current Affairs;
2.Expert member of China Health Policy and Technology Evaluation Research Association;
3.Zhongguancun Trina Technology Achievements Transformation Liaoning Province Promotion Association Medical Professional Committee Deputy Chairman;
4.Member of the Professional Committee of Health Technology Evaluation of Chinese Health Economics Association;
5.Member of the Standing Committee of the Health Policy Research Committee of the Liaoning Provincial Health Economics Association;
6.Member of the Pharmaceutical Economics Subcommittee of Liaoning Pharmaceutical Association;
7.Liaoning Provincial Philosophy and Social Science Achievement Award Subject Evaluation Group Expert;
8.《Member of the editorial board of "China Drug Evaluation", "China Medical Herald", "China Pharmaceutical" and other magazines.
Main Research Direction
Research direction 1: Health economic policy evaluation;
Research direction 2: Research on evaluation methods of pharmacoeconomics;
Research direction 3: Health technology assessment and medical market access policy research.
Scientific research projects presided over and participated in the past five years：
1.Research on the large-scale production mechanism of anti-tumor targeted drugs based on TRIZ theory, Liaoning Provincial Science and Technology Department Public Welfare Fund, 2017-2019;
2.Research on drug market access mechanism based on clinical value evaluation, Liaoning Provincial Department of Education, 2017-2018;
3.Study on the Economic Burden of Irritable Bowel Syndrome Type C Disease, AstraZeneca Pharmaceutical Co., Ltd., 2017-2018;
4.Research on the development strategy of pharmacoeconomics discipline construction in colleges and universities, the "13th Five-Year Plan" project of Liaoning Higher Education Association, 2015-2016;
5.Research on the Strategy of Cultivating Entrepreneurial Talents for Pharmaceutical Management Majors in Colleges and Universities Based on Technological Innovation, Liaoning Higher Education Association, 2016-2017;
6.Liaoning Provincial Biomedical Technology Information Monitoring, Liaoning Provincial Department of Science and Technology, 2016-2017;
7.Research on the Development Strategy of Biomedicine Industry Base in Liaoning Province, Science and Technology Department of Liaoning Province, 2015-2016;
8.Research on the expert report system for drug price review, commissioned by the National Development and Reform Commission, 2014.
Representative papers published in recent five years:
1.Analysis of the Utilization Status of Essential Medicines in Beijing’s Community Health Institutions,Therapeutic Innovation& Regulatory,2016,19（3）：24-29(SCI收录);
2.Economic burden of irritable bowel syndrome in China，World Journal of Gastroenterology，2016,22(47):10267-10476(SCI收录);
3..Is there a difference between EQ-5D and SF-6D in the clinical setting? a comparative study on the quality of life measured by AIMS2-SF, EQ-5D and SF-6D scales for osteoarthritis patients,International Journal of Rheumatic Diseases,2016,19（27）：11-28（SCI收录)；
4.The Australian Life Saving Drugs Program and its implications for medical assistance system for the rare diseases in China. Chinese Pharmaceutical Journal, 2015，8（8）：51-55;
5.International Reimbursement Policies on Drugs for Pulmonary Arterial Hypertension and Enlightenment to China. Chinese Pharmaceutical Journal, 2015，50（18）：1639-1642;
6.Pharmacoeconomic evaluation guidelines of Asian countries（or regions）and its implications for China. Chinese Journal of New Drugs, 2015，24（19）：2183-2187；
7.Assessment of Pharmacoeconomic Evaluation Literature of China in 2012 and 2014--According to Chinese Pharmacoeconomic Evaluation Guidelines（2011 edition）. China Journal of Pharmaceutical Economics, (IF=0.215).2015,8：12-17；
8.Construction Study of Index System to Evaluate the Clinical Value of Drugs. Chinese Pharmaceutical Journal, 2017，52（8）：706-710；
9.Selection and evaluation method of consistency evaluation. China medicine and pharmacy, 2017,7（2）：194-196；
10.Comparison of Research Support for Rare Diseases and Orphan Drugs Innovation in China and the United States. Chinese Pharmaceutical Journal，2016,52（13）:1152-1156。
Textbooks and monographs edited or participated in：
Application and case analysis of Pharmacoeconomics, editor-in-chief,Chemical Industry Press,2018.7
Research methodology of modernization of Traditional Chinese medicine,monographs,Liaoning Science Press,2010.8
